Infect Chemother. 2021 Sep;53(3):592-616. doi: 10.3947/ic.2021.0305. Epub 2021 Aug 5.
Since the establishment of the Committee for Clinical Guidelines for the Diagnosis and Treatment of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) by the Korean Society for AIDS in 2010, clinical guidelines have been prepared in 2011, 2013, 2015, and 2018. As new research findings on the epidemiology, diagnosis, and treatment of AIDS have been published in and outside of Korea along with the development and introduction of new antiretroviral medications, a need has arisen to revise the clinical guidelines by analyzing such new data. The clinical guidelines address the initial evaluation of patients diagnosed with HIV/AIDS, follow-up tests, appropriate timing of medication, appropriate antiretroviral medications, treatment strategies for patients who have concurrent infections with hepatitis B or C virus, recommendations for resistance testing, treatment for patients with HIV and tuberculosis coinfections, and treatment in pregnant women. Through these clinical guidelines, the Korean Society for AIDS and the Committee for Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS contributes to overcoming AIDS by delivering latest data and treatment strategies to healthcare professionals who treat AIDS in the clinic.
自韩国艾滋病协会于2010年成立人类免疫缺陷病毒/获得性免疫缺陷综合征（HIV/AIDS）诊断与治疗临床指南委员会以来，分别于2011年、2013年、2015年和2018年制定了临床指南。随着新的抗逆转录病毒药物的研发和引入，韩国国内外陆续发表了关于艾滋病流行病学、诊断和治疗的新研究成果，因此有必要通过分析这些新数据来修订临床指南。临床指南涉及HIV/AIDS确诊患者的初始评估、随访检测、用药的合适时机、合适的抗逆转录病毒药物、合并乙型或丙型肝炎病毒感染患者的治疗策略、耐药性检测建议、HIV与结核病合并感染患者的治疗以及孕妇的治疗。通过这些临床指南，韩国艾滋病协会以及HIV/AIDS诊断与治疗临床指南委员会为临床治疗艾滋病的医护人员提供最新数据和治疗策略，从而为攻克艾滋病做出贡献。
